搜索
Urogen Pharma Ltd
URGN添加自选
28.780USD
-0.900-3.03%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.35B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.03%
5天
-2.11%
1月
+34.55%
6月
+21.13%
今年开始到现在
+22.89%
1年
+293.71%
TradingKey Urogen Pharma Ltd股票评分
单位: USD 更新时间: 2026-05-15操作建议
Urogen Pharma Ltd当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名13/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价36.11。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Urogen Pharma Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Urogen Pharma Ltd亮点
亮点风险
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
业绩高增长
公司营业收入稳步增长，连续3年增长32.73%
利润高增长
公司净利润处于行业前列，最新年度总收入109.79M美元
估值低估
公司最新PE估值-10.52，处于3年历史低位
机构减仓
最新机构持股46.29M股，环比减少25.32%
默里·斯塔尔持仓
明星投资者默里·斯塔尔持仓，最新持仓市值1.18K
分析师目标
根据
9
位分析师
买入
评级
36.111
目标均价
+21.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Urogen Pharma Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Urogen Pharma Ltd简介
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
公司代码URGN
公司Urogen Pharma Ltd
CEOBarrett (Elizabeth A)
网址https://www.urogen.com/
相关品种
